Results for: remission Search Results
Family Filter:
15:28
Balanced Health Today Call Now 1(888)277-4980 Gorham's disease is a rare bone disorder characterized by bone loss (osteolysis), often associated abnormal blood vessel growth (angiomatous proliferation). Bone loss can occur in just one bone, or spread to soft tissue and adjacent bones. Symtoms may include pain, swelling, and increased risk of fracture.[1] It may affect any part of the skeleton, but most commonly involves the skull, collarbone (clavicle), pelvis, ribs, spine, and/or jaw. Depending on the bones affected, various complications may occur. The cause of Gorham's disease is currently unknown. Most cases occur sporadically. Treatment is based on the signs and symptoms in each affected person, and most commonly involves surgery and/or radiation therapy. In some cases, Gorham's disease improves without treatment (spontaneous remission). Gorham’s (GOR-amz) disease is a very rare skeletal condition of uncertain etiology, characterized by the uncontrolled proliferation of distended, thin-walled vascular or lymphatic channels within bone, which leads to resorption and replacement of bone with angiomas and/or fibrosis. Because of the loss of the affected bone, the condition has been referred to as disappearing bone disease, vanishing bone disease, and massive osteolysis. In medical terminology osteolysis means: bone (osteo) breaking down or destruction (lysis). The first known report of the condition came in 1838 in an article titled “A Boneless Arm” in what was then The Boston Medical and Surgical Journal, now The New England Journal of Medicine. It is a brief but fascinating report chronicling the case of Mr. Brown who had, in 1819 at age 18 years, broken his right upper arm in an accident. The patient suffered two subsequent accidents, which fractured the arm twice more “before the curative process had been completed.” At the time of the report in 1838 the patient was reported as having remarkable use of the arm, in spite of the humerus bone having....
3 Apr 2017
36
Share Video

2:47
remission was composed in 2009 by åge riisnes. (c) 2010 harlequins enigma. this is the hd version, plz vote / comment :]
15 Aug 2010
351
Share Video

1:33
*******sarcoidosis-remission.bonuscb**** - Sarcoidosis Remission - Sarcoidosis Symptoms Attention! Close the door and turn off your cell phone. Take a couple of minutes for yourself and and learn how to finally eradicate sarcoidosis forever. Guaranteed! “At Last, You Can Stop Suffering the Living Hell of Sarcoidosis With Natural Alternatives and Without Drugs or Surgery!” Quotation: Jani Hajjri, health specialist and alternative medicine researcher, Chicago - Illinois, Oct. 2006: "All the efforts to send the "message" to the immune system of a sarcoid sufferer that there's nothing wrong and there's no need for such extreme reactions fail tragically unless care is taken to..." The Aden protocol is a system which first stirred the waters back in November 2004 and is doing so to date. It is the only protocol in existence that was proven to induce remission in sarcoidosis patients. Just to eliminate any doubts, before you go any further, claim your free report that will give you a comprehensive overview of the science behind the Aden protocol. *******sarcoidosis-remission.bonuscb****
18 Aug 2010
370
Share Video

1:33
*******sarcoidosis-remission.bonuscb**** - Sarcoidosis Remission - Sarcoidosis Symptoms Attention! Close the door and turn off your cell phone. Take a couple of minutes for yourself and and learn how to finally eradicate sarcoidosis forever. Guaranteed! “At Last, You Can Stop Suffering the Living Hell of Sarcoidosis With Natural Alternatives and Without Drugs or Surgery!” Quotation: Jani Hajjri, health specialist and alternative medicine researcher, Chicago - Illinois, Oct. 2006: "All the efforts to send the "message" to the immune system of a sarcoid sufferer that there's nothing wrong and there's no need for such extreme reactions fail tragically unless care is taken to..." The Aden protocol is a system which first stirred the waters back in November 2004 and is doing so to date. It is the only protocol in existence that was proven to induce remission in sarcoidosis patients. Just to eliminate any doubts, before you go any further, claim your free report that will give you a comprehensive overview of the science behind the Aden protocol. *******sarcoidosis-remission.bonuscb****
17 Aug 2010
135
Share Video

0:56
*******www.supportmissionremission**** We have begun our prelaunch phase, donating 60% of all book sales to the Empire DragonBoat Breast Cancer Survivor Team. Distributed by Tubemogul.
30 Dec 2010
58
Share Video

0:59
*******www.SupportMissionReMission**** Distributed by Tubemogul.
3 Jan 2011
77
Share Video

1:02
Help support our campaign: *******www.supportmissionremission**** Distributed by Tubemogul.
5 Jan 2011
70
Share Video

2:40
Jessica Moser shares her story about surviving cancer and why she wants others to support *******www.supportmissionremission**** Distributed by Tubemogul.
7 Jan 2011
118
Share Video

1:59
Chris shares her story about the postitive effects of having a support group. To donate and help this cause go to *******www.supportmissionremission**** Distributed by Tubemogul.
9 Jan 2011
78
Share Video

3:38
*******www.supportmissionremission**** Help us bring in the new year with our Mission to donate $1 million to Support Groups for Cancer Survivors. I explain my story and what inspired me to launch this campaign. Distributed by Tubemogul.
16 Jan 2011
58
Share Video

1:56
This Hypnosis recording is free from *******www.debbiewilliamsassociates******/free_download.htm#free_download it doesn't claim to 'cure' and is in no way a replacement for appropriate medical advice, it uses hypnotic language to plant seeds to release stress as well as taking the mind on a relaxing journey
4 Dec 2012
75
Share Video

2:01
The Humble THQ Bundle succeeds and other news from around the gaming world today on Hard News.
5 Dec 2012
6379
Share Video

4:34
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
19 Dec 2013
68
Share Video

0:27
FDA Approves LIALDA™ (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis Basingstoke, UK and Philadelphia, US - January 16, 2007 / PRNewswire / — Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that the U.S. Food and Drug Administration (FDA) has approved LIALDA™ (mesalamine) with MMX® technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. LIALDA is the first and only FDA-approved once-daily oral formulation of mesalamine. Mesalamines are a part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA), a well-established drug of choice and often a first-line treatment for patients with mild to moderate ulcerative colitis. Shire will launch LIALDA in the U.S. in the first quarter of 2007. Once-daily LIALDA with MMX technology contains the highest mesalamine dose per tablet (1.2 g), so patients can take as few as two tablets once daily. Other currently available mesalamines require three to four times daily dosing and 6 to 16 pills a day. A recent study conducted by the Crohn's and Colitis Foundation of America (CCFA) found that 65 percent of patients with ulcerative colitis are poorly compliant with their medication, citing pill burden and inconvenience associated with the medication. "As the first oral once-a-day treatment option for ulcerative colitis, the approval of LIALDA in the United States is great news for patients and physicians when managing this serious condition," said Matthew Emmens, Shire Chief Executive Officer. "Once-daily LIALDA is one of several medicines Shire expects to launch in the U.S. and Europe in 2007." The FDA approval was based on the results of two Phase III clinical studies that found LIALDA (2.4 g/day and 4.8 g/day) was effective in inducing remission in patients with active, mild to moderate ulcerative colitis compared to placebo after eight weeks of treatment. LIALDA is generally well tolerated and has a similar safety profile to other currently available mesalamines. "In clinical trials, LIALDA proved to be an effective medication, providing superior rates of remission compared to placebo for people with ulcerative colitis," said lead study investigator, Gary R. Lichtenstein, M.D., director of the Center for Inflammatory Bowel Diseases at the Hospital of the University of Pennsylvania. "This is the first new mesalamine treatment to enter the market since 2000, filling a major void for physicians and people with ulcerative colitis and simplifying treatment of this disease." "The introduction of new treatments with more convenient dosing regimens may be an important step in helping patients with ulcerative colitis remain compliant with their medication," said Jonathan Braun, M.D., Ph.D., chair of CCFA's National Scientific Advisory Committee. Shire has licensed from Giuliani S.p.A. the exclusive rights to develop and commercialize LIALDA in the U.S., Canada, Europe -- known as MEZAVANT™ -- (excluding Italy) and the Pacific Rim. Giuliani S.p.A. retains the development and commercialization rights in Italy. Cosmo Pharmaceuticals S.p.A., Milan developed the MMX technology and owns the trademark, MMX. For more information on LIALDA, please visit www.LIALDA****.
18 Jan 2007
1709
Share Video

4:35
The U.S. Food and Drug Administration (FDA) has approved Reclast (zoledronic acid) injection for the treatment of Pagets disease of the bone, the second most prevalent bone disease after osteoporosis. Reclast is the first and only single dose treatment regimen for Pagets disease and the first new treatment for the disease in nearly a decade. Until today, standard therapies for Pagets disease bisphosphonates taken in pill form had to be taken daily for up to six months. Reclast is given as a single 15 minute intravenous infusion by a healthcare professional. Studies show that Reclast is more effective, offers a longer period of remission and starts working faster than the current standard treatment, Actonel (risedronate sodium). Reclast works by attaching to bone, stopping excessive bone breakdown and rebalancing the bodys natural bone remodeling process. The FDA is currently reviewing Reclast as a potential once yearly treatment for postmenopausal osteoporosis. For additional information on Reclast, visit www.reclast****. For more information about Pagets disease, please contact The Paget Foundation at www.paget**** or call 800-23-PAGET (800-237-2438).
18 Apr 2007
2538
Share Video

0:34
My acne had totally disappeared in only 3 days! I finally had the clear skin that I had always wanted, and my confidence and self-esteem went through the roof! Still I worried it might return. As with previous attempts to put my acne into remission, there would be brief moments of success followed by the inevitable disappointment several days or weeks later
16 Nov 2007
543
Share Video